ACTH-dependent Cushing syndrome

Summary

ACTH-dependent Cushing syndrome (MONDO:0020528) is a disease. A subtype of hyperpituitarism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.55	Worldwide	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	ACTH-dependent Cushing syndrome
Mondo ID	MONDO:0020528
EFO	EFO:1001110
MeSH	D047748
Orphanet	99892
DOID	DOID:3946
ICD-10-CM	E24.0
ICD-11	212778081
SNOMED CT	190502001, 237734007
UMLS	C0342442
MedGen	575036
GARD	0019699
MedDRA	10035109
Is cancer (heuristic)	no

Also known as: ACTH hypersecretion, pituitary · ACTH-dependent CS · adrenocorticotropic hormone, inappropriate secretion · adrenocorticotropic hormone-dependent Cushing syndrome · corticotropin-dependent Cushing syndrome · pituitary Cushing disease · pituitary Cushing diseases · pituitary Cushing syndrome · pituitary-dependent Cushing’s disease

Disease family

This is a subtype of hyperpituitarism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › pituitary gland disorder › anterior pituitary gland disorder › hyperpituitarism › ACTH-dependent Cushing syndrome

Related subtypes (3): hyperprolactinemia, acromegaly, pituitary gigantism

Subtypes (2): Cushing disease due to pituitary adenoma, ectopic Cushing syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Levoketoconazole	Phase 3 (in late-stage trials)
Mifepristone	Phase 3 (in late-stage trials)
Osilodrostat	Phase 3 (in late-stage trials)
Pasireotide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cabergoline, Prednisolone, Vorinostat.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.